After reading this article, you should be able to: Identify patients at risk of developing an AKI; Define and recognise the signs and symptoms of AKI; Outline the management options for AKI; Summarise for AKI; Recognise that disease modifying medications for cardiovascular disease and chronic kidney disease, such as angiotensin-converting enzyme inhibitors/ angiotensin II receptor blockers and sodium-glucose cotransporter 2 inhibitors, are not to be labelled ‘nephrotoxic’.
